Piedmont Investment Advisors LLC raised its position in Allergan PLC. (NYSE:AGN) by 0.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,044 shares of the company’s stock after buying an additional 504 shares during the period. Piedmont Investment Advisors LLC’s holdings in Allergan PLC. were worth $16,974,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of the company. Charter Trust Co. acquired a new stake in Allergan PLC. during the first quarter worth approximately $213,000. First National Bank of Omaha raised its stake in Allergan PLC. by 1.6% in the first quarter. First National Bank of Omaha now owns 50,780 shares of the company’s stock worth $12,132,000 after buying an additional 800 shares during the last quarter. Verde Servicos Internacionais S.A. raised its stake in Allergan PLC. by 22.0% in the first quarter. Verde Servicos Internacionais S.A. now owns 101,977 shares of the company’s stock worth $24,364,000 after buying an additional 18,387 shares during the last quarter. Horan Capital Management raised its stake in Allergan PLC. by 21.4% in the first quarter. Horan Capital Management now owns 38,717 shares of the company’s stock worth $9,250,000 after buying an additional 6,836 shares during the last quarter. Finally, BKD Wealth Advisors LLC acquired a new stake in Allergan PLC. during the first quarter worth approximately $219,000. 84.77% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC. (AGN) traded up 0.31% during trading on Friday, hitting $232.92. The stock had a trading volume of 843,449 shares. The firm has a market cap of $78.07 billion, a P/E ratio of 7.10 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a 50 day moving average price of $246.34 and a 200 day moving average price of $238.00.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period in the prior year, the company posted $3.35 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities analysts expect that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.
ILLEGAL ACTIVITY WARNING: “Allergan PLC. (NYSE:AGN) Shares Bought by Piedmont Investment Advisors LLC” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/08/11/allergan-plc-nyseagn-shares-bought-by-piedmont-investment-advisors-llc.html.
A number of analysts have commented on AGN shares. Citigroup Inc. reissued a “focus list” rating and issued a $261.27 target price (up previously from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Royal Bank Of Canada lifted their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price for the company. in a report on Wednesday, May 10th. UBS AG reissued a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Eight equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $274.49.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.